Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor

Cancer Gene Therapy

Volumn 9, Issue 2, 2002, Pages 117-125

  Eder, Iris E ^a   Hoffmann, Jens ^b   Rogatsch, Hermann ^c   Schäfer, Georg ^c   Zopf, Dieter ^b   Bartsch, Georg ^a   Klocker, Helmut ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Antisense oligonucleotide; Downregulation; Human androgen receptor; LNCaP; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TUMOR CELL LINE; TUMOR VOLUME; WEIGHT REDUCTION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; DNA PRIMERS; DOWN-REGULATION; GENE THERAPY; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MALE; MICE; MICE, NUDE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS;

EID: 85047697645     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700416     Document Type: Article

References (49)

1. Some aspects of relation of structure of steroids to their prostate stimulating effects
2. Hormonal therapy for prostate cancer
3. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation
4. Antisense oligodeoxynucleotides
5. Gene inhibition using antisense oligodeoxynucleotides
6. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides
7. Antitumor activity of a phoshorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
8. Induction of apoptosis in small cell lung cancer cells by antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence
9. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
10. Antisense approaches enter the clinic
11. Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides
12. Update of the androgen receptor gene mutations database
13. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor
14. Activation of the human androgen receptor through a protein kinase A signaling pathway
15. Hyperactive androgen receptor in prostate cancer: What does it mean for new therapy concepts?
16. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
17. Distant metastases from prostatic carcinoma express androgen receptor protein
18. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
19. Antitumor activity of a c-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice
20. Phase I clinical/pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
21. A phase I trial of C-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer
22. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production
23. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-a, in patients with advanced cancer
24. Phase I study of an antisense oligonucleotide to protein kinase C-a (ISIS 3521/CGP 64128A) in patients with cancer
25. Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis
26. Antisense bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model
27. Inhibition of progression to androgen-indepence by combined adjuvant treatment with antisense BCL-X and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model
28. Down-regulation of p21WAF1/CIP1 or p27Kipl abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells
29. Vascular endothelial growth factor as a target for cancer gene therapy
30. Antisense IGF and antisense IGF-IR therapy of malignancy
31. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
32. Combination therapy for prostate cancer-endocrine and biologic basis of its choice as new standard first-line therapy
33. Androgen receptor status of lymph node metastases from prostate cancer
34. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens
35. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone
36. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor
37. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways
38. Steroid hormone receptors: Evolution, ligands, and molecular basis of biologic function
39. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: Structure-immunostimulatory activity relationships
40. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical?
41. Does antisense exist?
42. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal therapy of lymphoma
43. Antisense oligonucleotides intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice
44. Lack of toxicity associated with the systemic administration of antisense oligonucleotides for treatment of rats bearing LNCaP prostate tumors
45. Antisense methods for discrimination of phenotypic properties of closely related gene products: Jun kinase family
46. High frequency regression of established human prostate carcinoma PC3 xenografts by systemic treatment with antisense JUN kinase
47. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes
48. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and-independent human xenograft models
49. Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence